Nagi Bioscience SA, a Lausanne, Switzerland–based life-science-tech company developing technology for the in vitro testing of drugs and chemicals, closed a CHF1.8m seed financing round.

Backers included investiere, Zürcher Kantonalbank, NEST pension fund and private investors from Switzerland and United States.

The company intends to use the funds to complete the development of its first product and prepare its market access.

Nagi Bioscience has already prototypes under validation in collaboration with key industrial players in the chemical and biotech fields.

Furthermore, the company announced the assignment of Dr. Chris Radloff to the Board of Directors. | To read full story, visit https://startuparound.com/read/1577102411.9486597/Nagi-Bioscience-Raises-CHF-1.8M-in-Seed-Funding?ref=audio_experience